With Lundbeck steering its R&D engine toward increasingly specialized neuroscience targets, the Danish drugmaker is plotting a U.S. HQ move to one of the country’s preeminent biopharma hotspots.
From its original U.S. home base in Deerfield, Illinois, Lundbeck now plans to relocate its local headquarters to Greater Boston, Massachusetts, where it says it will set up a global innovation hub.
The Danish company framed the move in a Sept. 25 release as part of its ongoing investment in the U.S., adding that the change should buoy efforts to scale its neuroscience portfolio, build out its artificial intelligence bona fides and “expand innovation opportunities.”
Key to the decision is Boston’s bustling network of academic and healthcare institutions, not to mention biotechs, technology and AI firms, and a robust scientific talent pool, Lundbeck said in its release.
The move will also bring Lundbeck’s main base of U.S. operations closer to its existing presence in nearby Cambridge.
"As we enter the next phase of our Focused Innovator strategy, our focus is on scaling the opportunities we have created, from our growing portfolio and pipeline to innovation and AI,” said Charl van Zyl, Lundbeck’s CEO, in a statement. “Our investment in Greater Boston is an important step in positioning Lundbeck to capture those opportunities and bring innovative treatments to more people living with brain diseases."
The headquarters transition will play out over the next year, with Lundbeck noting that it aims to retain the “people, expertise and capabilities that have delivered exceptional performance while continuing to serve patients and partners without disruption.”
Lundbeck did not specify its plans for the site it’s exiting in Deerfield, nor did it share financial details on the new HQ.
Over the first half of 2026, Lundbeck posted sales growth of 16%, propelled by brands like migraine preventative Vyepti and the Otuska-partnered Rexulti, an atypical antipsychotic cleared across major depressive disorder, schizophrenia and agitation from Alzheimer’s disease dementia.
That is “healthy growth for us,” CEO van Zyl told Fierce in a recent interview, noting that Vyepti in particular could clinch peak U.S. sales of $1.1 billion, with other opportunities for the drug coming online in Europe and more market openings potentially on the way in China, Japan and Southa Korea next year.
As for the innovation Lundbeck is aiming for these days, van Zyl said that the company has increasingly moved toward indications “where we believe we understand the biology of neuroscience more,” leading to what he branded more of a “neurospecialty” focus versus a purely psychiatric line of sight.
In practice, this means capitalizing on present prospects like Vyepti’s foray into migraine prevention, plus potential opportunities in diseases like Parkinson’s further down the line.
Meanwhile, beyond the next-generation assets advancing through Lundbeck’s pipeline, the company will also “be acquisitive,” according to van Zyl, who said that “we look very much at external and internal innovation and business development that makes sense for us.”
Wherever the company’s interest may fall next, Lundbeck will almost certainly have a spread of options available to it once it settles into the new digs in Boston.